Evidence map›Paper›PMID 31855073›Full record

ArticleIntegrative cancer therapies

Qi-Hao Zhang, Qin-Xiao Hu, Da Xie, Bo Chang, Hou-Guang Miao, Yun-Guo Wang, De-Zhong Liu, Xue-Dong Li

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. A Polysaccharide Purified FromFrontiers in immunology · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qi-Hao ZhangThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Qin-Xiao HuThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Da XieThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Bo ChangThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Hou-Guang MiaoThe Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong, People's Republic of China.
Yun-Guo WangThe Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China.
De-Zhong LiuThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Xue-Dong LiThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.ORCID 0000-0001-6482-9369
Shantou University · CNShenzhen University · CNSecond Hospital of Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Apoptosisbeta CateninBiological ProductsCell CycleCell DeathCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9OsteosarcomaReishiWnt Signaling Pathwaybeta CateninBiological ProductsCTNNB1 protein, humanMatrix Metalloproteinase 2Matrix Metalloproteinase 9anticancer activityGanoderma lucidumLRP5osteosarcomaWnt/β-catenin signaling

Identifiers

PMID31855073
PMCPMC6923688
OpenAlexW2995078919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.